9 results
Stroke and bleeding risk stratification with the CHADS2-VASc and HAS-BLED schemas

#Diagnosis #Hematology #CHADS2 #CHADS2VASc #HASBLED #Comparison
Stroke and bleeding ... risk stratification ... #Diagnosis #Hematology ... CHADS2 #CHADS2VASc #HASBLED ... #Anticoagulation
Bleeding risk calculators - HAS-BLED (atrial fibrillation) and IMPROVE (VTE prophylaxis for inpatients)
Important notes:
 • No
Bleeding risk calculators ... of withholding anticoagulation ... risk #HASBLED ... Calculators #Anticoagulation ... #Factors #Hematology
CHA2DS2VASc vs HAS-BLED scores for stroke risk and bleed risk on anticoagulation

C	Congestive Heart Failure	1

H	Hypertension	1

A2	Age >75	2

D	Diabetes Mellitus	1

S2	Stroke,
risk on anticoagulation ... 1 B Bleeding ... CHADS2 #CHADS2VASc #HASBLED ... #Anticoagulation ... AFib #Diagnosis #Hematology
HAS-BLED Score - Risk of Major Bleeding in 1 Year
Characteristics (1 point each)
 • Hypertension: Baseline
HAS-BLED Score - Risk ... of Major Bleeding ... EricsMedicalLectures/ #HASBLED ... #Score #Risk #Bleeding ... #anticoagulation
HAS-BLED Score
 - Hypertension: Baseline SBP > 160mmHg
 - Renal disease: Cr > 2.6mg/dL, on HD,
- History of stroke ... Eric Strong https ... DrEricStrong #HASBLED ... #Risk #Score #Bleeding ... #Anticoagulation
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
patients at high risk ... of bleeding. ... risk during follow-up ... #Anticoagulation ... #Management #Hematology
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
Preoperative Risk ... event, follow ACC algorithm ... Anticoagulation ... - what is the bleeding ... • <6mo since stroke
Longterm Venous Thromboembolism Treatment Algorithm
Treat for 3 months and reassess
 • Isolated distal DVT (without cancer)
Thromboembolism Treatment Algorithm ... PE - High Bleeding ... - Not High Bleeding ... #management #hematology ... #anticoagulation
Essential Thrombocythemia (ET)
ET is a chronic myeloproliferative neoplasm. Most cases are related to mutations that affect
• Treatment algorithms ... appropriate only for low risk ... patients with no CV risk ... Hydroxyurea + anticoagulation ... Thrombocythemia #ET #hematology